|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Ohr Pharmaceutical, Inc.
| | | Phone: | (212) 682-8452 | Year Established: | 2008 | Ticker: | OHRP | Exchange: | NASDAQ | Main Contact: | Sam Backenroth, CFO & VP, Business Development | | Other Contacts: | Irach Taraporewala, CTO Avner Ingerman, M.D., Chief Clinical Officer Marlene Modi, Ph.D., Head of Preclinical and Regulatory Affairs Peter K. Kaiser, MD, Head of Product Development Glenn L. Stoller, MD, CSO Mike Ferguson, Chairman Jason S. Slakter, MD, CEO
| | Company Description | Ohr Pharmaceutical is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. | |
|
|
|
|
|